Eprex 4000Iu Syringe

Eprex 4000Iu Syringe

Description:

Eprex 4000 iu/0.4 ml prefilled syringe is a prescription medicine containing recombinant human erythropoietin (epoetin alfa), an erythropoiesis-stimulating agent used to treat certain types of anemia. It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells and mimics the natural hormone erythropoietin, which stimulates red blood cell production in the bone marrow. Eprex is supplied as ready-to-use prefilled syringes for subcutaneous or intravenous injection under medical supervision, commonly used in patients with chronic kidney disease, patients on dialysis, patients undergoing renal transplantation, and some patients receiving specific HIV therapies or chemotherapy-associated anemia as per physician judgment.

Indications:

• Treatment of anemia associated with chronic kidney disease (CKD) in adults and children on hemodialysis or peritoneal dialysis, and in patients with severe renal insufficiency not yet on dialysis, as prescribed by a physician.
• Treatment of symptomatic anemia in adult patients with renal transplants, to improve hemoglobin levels and reduce the need for blood transfusions (as per physician guidance).
• Treatment of anemia associated with certain HIV therapies (e.g., zidovudine-induced anemia) in HIV-infected patients, when recommended by a specialist.
• Reduction of transfusion requirements in selected patients with anemia due to chemotherapy or other causes, according to clinical guidelines and physician decision.
• Improves symptoms related to anemia such as fatigue, weakness, shortness of breath, reduced exercise capacity, and pallor when due to low red blood cell count.

Active Ingredients / Key Components:

• Epoetin alfa (recombinant human erythropoietin) – 4000 iu per 0.4 ml prefilled syringe.
• Concentration: 10000 iu/ml solution for injection (4000 iu in 0.4 ml).
• Excipients (full list not available): may include buffer components, sodium chloride, and stabilizers – exact composition not fully available in the provided information. Refer to the official package leaflet for the complete excipient list.

Dosage & Administration / How to Use:

• Eprex 4000 iu must be used exactly as prescribed by a physician experienced in the management of anemia and erythropoiesis-stimulating agents.
• Route of administration: subcutaneous (under the skin) or intravenous (into a vein), depending on the clinical situation and doctor’s instructions. In dialysis patients, intravenous administration via the dialysis line is common.
• Typical starting doses for chronic kidney disease or dialysis-related anemia are usually calculated based on body weight and hemoglobin level (e.g., 50–100 iu/kg 1–3 times per week), but exact dosing, titration, and frequency must be determined individually by the treating physician.
• Do not shake the syringe. Shaking can denature the protein and reduce effectiveness.
• Allow the prefilled syringe to reach room temperature (about 15–30 minutes) before injection, without using external heat sources.
• Inspect the solution visually: it should be clear and colorless to slightly opalescent, without visible particles. Do not use if the solution is cloudy, discolored, or contains particles, or if the syringe is damaged.
• For subcutaneous injection: usually injected into the thigh, abdomen, or upper arm. Rotate injection sites to reduce local irritation. Use aseptic technique (clean the skin with an antiseptic swab before injection).
• Do not attempt self-injection unless you have been trained by a healthcare professional. Follow the step-by-step technique demonstrated by your doctor or nurse.
• Dosage adjustments: the doctor will regularly monitor hemoglobin levels and adjust the dose to maintain target hemoglobin, avoiding excessively high levels to reduce the risk of cardiovascular events.
• If a dose is missed, contact your doctor for advice. Do not double the dose to make up for a missed injection.
• Use only one syringe per patient per administration. Do not reuse needles or syringes. Dispose of used syringes safely in a sharps container according to local regulations.

Clinical Benefits:

• Helps stimulate red blood cell production in the bone marrow, correcting anemia caused by chronic kidney disease or certain medications.
• Reduces the need for blood transfusions and associated risks (e.g., transfusion reactions, iron overload, and infection transmission) in appropriately selected patients.
• Improves anemia-related symptoms such as fatigue, weakness, dizziness, shortness of breath, and reduced exercise tolerance, supporting better quality of life.
• Supports better oxygen-carrying capacity of the blood by increasing hemoglobin and hematocrit levels when used and monitored correctly.

Warnings & Contraindications:

• Use only under strict medical supervision. Eprex is a potent erythropoiesis-stimulating agent and inappropriate use can lead to serious side effects.
• Contraindicated in patients with known hypersensitivity to epoetin alfa, other erythropoietins, or any component of the formulation.
• Contraindicated in patients with uncontrolled hypertension. Blood pressure must be well controlled before and during treatment.
• Use with extreme caution in patients with a history of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction) or those at high risk for thrombosis.
• Monitor hemoglobin regularly. Rapid rises or excessively high hemoglobin levels increase the risk of serious cardiovascular events (heart attack, stroke, thrombosis).
• Pure red cell aplasia (PRCA) has been reported rarely with erythropoiesis-stimulating agents. If there is a sudden loss of effect and severe anemia develops, treatment must be stopped and appropriate investigations performed.
• Use with caution in patients with liver disease, epilepsy, or a history of seizures, and in those with hematologic disorders other than anemia of CKD or drug-induced anemia.
• Iron status should be assessed and corrected if necessary (iron supplementation) to optimize response to epoetin alfa.
• Consult your doctor before use if pregnant, nursing, taking other medications (especially antihypertensives, anticoagulants, or chemotherapy), or if you have medical conditions such as cardiovascular disease, hypertension, clotting disorders, or malignancy.
• Not intended for use as a performance-enhancing drug in sports. Misuse may lead to serious cardiovascular complications and is prohibited by anti-doping regulations.
• Keep out of reach of children.

Side Effects:

• Common side effects: headache, flu-like symptoms (fever, chills, muscle aches), injection site reactions (pain, redness, swelling), nausea, vomiting, and mild skin rash.
• Increased blood pressure or worsening of pre-existing hypertension may occur; regular blood pressure monitoring is essential.
• Less common but serious side effects: thromboembolic events (blood clots in veins or arteries), stroke, heart attack, seizures, and hypertensive crisis.
• Very rare: pure red cell aplasia (PRCA) leading to severe anemia and low reticulocyte count; if suspected, treatment must be stopped immediately and medical evaluation is required.
• Allergic or anaphylactic reactions (swelling of face, lips, tongue, difficulty breathing, severe rash) are rare but require immediate medical attention.
• If you experience chest pain, sudden shortness of breath, severe headache, confusion, weakness on one side of the body, or vision changes, seek emergency medical care immediately.

Storage Instructions:

Store Eprex 4000 iu/0.4 ml prefilled syringes in a refrigerator at 2–8 °c. Do not freeze. Keep the syringe in the original carton to protect it from light. If accidentally frozen, do not use. Do not shake the syringe. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Specifications:

• Product type: medicine – erythropoiesis-stimulating agent (epoetin alfa).
• Strength: 4000 iu epoetin alfa per 0.4 ml prefilled syringe (concentration 10000 iu/ml).
• Form: solution for injection in prefilled syringe.
• Pack size: commonly available as 6 prefilled syringes per pack (e.g., Eprex 4000 iu/0.4 ml 6 prefilled syringes).
• Route of administration: subcutaneous or intravenous, as directed by a healthcare professional.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.